ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CKPT Checkpoint Therapeutics Inc

1.42
-0.02 (-1.39%)
Apr 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 166,058
Bid Price 1.41
Ask Price 1.52
News -
Day High 1.50

Low
1.30

52 Week Range

High
3.62

Day Low 1.41
Company Name Stock Ticker Symbol Market Type
Checkpoint Therapeutics Inc CKPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -1.39% 1.42 18:50:20
Open Price Low Price High Price Close Price Prev Close
1.50 1.41 1.50 1.42 1.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
922 166,058 $ 1.45 $ 240,786 - 1.30 - 3.62
Last Trade Time Type Quantity Stock Price Currency
19:29:34 10 $ 1.42 USD

Checkpoint Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
33.41M 23.53M - 103k -51.85M -2.20 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Checkpoint Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CKPT Message Board. Create One! See More Posts on CKPT Message Board See More Message Board Posts

Historical CKPT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.681.72161.411.48444,482-0.26-15.48%
1 Month2.072.101.411.72358,435-0.65-31.40%
3 Months2.052.3551.411.93420,434-0.63-30.73%
6 Months2.003.621.362.13653,385-0.58-29.00%
1 Year3.033.621.302.20453,178-1.61-53.14%
3 Years28.3046.401.3018.27646,480-26.88-94.98%
5 Years34.6053.7621.3022.23608,812-33.18-95.90%

Checkpoint Therapeutics Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Your Recent History

Delayed Upgrade Clock